Q-State Biosciences
As President of Proximagen, an early clinical stage drug development company, Dr. William Pullman oversees the company’s strategic direction and scientific affairs, including pipeline selection and development, and all clinical, medical, and regulatory operations. Before joining Proximagen, William served as Chief Scientific Officer of Upsher-Smith Laboratories. He also formerly held positions as Chief Research and Development Officer and Chief Development Officer at Dyax Corp., Chief Medical Officer at Cubist Pharmaceuticals, and Senior Vice President, Exploratory Development at TransForm Pharmaceuticals. William completed his primary medical training at the University of Western Australia and is a fellow of the Royal Australian College of Physicians. He also received his PhD in Medicine and Clinical Science (Immunology) from the Australian National University.
This person is not in the org chart
This person is not in any teams
Q-State Biosciences
Q-State Biosciences is a technology-derived medicines company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering, and AI/machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.